[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334805-105":59,"doc-detail-334805-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","current-treatment-strategies-for-ovarian-cancer-in-the-east-asian-gynecologic-oncology-trial-group-eagot","Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT)","","Ovarian cancer, known for its poor prognosis among gynecologic malignancies, has experienced rapid advances in therapeutic approaches. Recent improvements include refined chemotherapy regimens and the incorporation of poly(ADP-ribose) polymerase (PARP) inhibitors as maintenance therapy. Outcomes have been enhanced particularly for patients with favorable molecular profiles, including BRCA mutation positivity and homologous recombination deficiency (HRD). The review also addresses approaches such as intraperitoneal chemotherapy administration and related EAGOT-driven treatment strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-treatment-strategies-for-ovarian-cancer-in-the-east-asian-gynecologic-oncology-trial-group-eagot/334805/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-treatment-strategies-for-ovarian-cancer-in-the-east-asian-gynecologic-oncology-trial-group-eagot/334805.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What recent advances are highlighted for ovarian cancer treatment?","Question",{"text":112,"@type":113},"The document highlights improved chemotherapy protocols and the use of PARP inhibitors as maintenance therapy, contributing to better outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which patient groups benefit most from PARP inhibitor maintenance?",{"text":117,"@type":113},"Patients with specific genetic or molecular profiles, including BRCA mutations and homologous recombination deficiency (HRD), are specifically noted.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does intraperitoneal chemotherapy play in the treatment strategies?",{"text":121,"@type":113},"The review addresses intraperitoneal chemotherapy administration as part of the current strategy set discussed for ovarian cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334805,1790912305,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","J Gynecol Oncol. 2024 May;35(3):e87 [https://doi.org/10.3802/jgo.2024.35.e87](https://doi.org/10.3802/jgo.2024.35.e87)[ ](https://doi.org/10.3802/jgo.2024.35.e87)pISSN 2005-0380·eISSN 2005-0399  \nReview Article  \nReceived: Mar 24, 2024  \nAccepted: Mar 24, 2024  \nPublished online: Apr 3, 2024  \nCorrespondence to  \nMuneaki Shimada  \nDepartment of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. [Email: muneaki.shimada.b7@tohoku.ac.jp](Email: muneaki.shimada.b7@tohoku.ac.jp)  \n© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nYusuke Kobayashi  [https://orcid.org/0000-0002-4503-2845](https://orcid.org/0000-0002-4503-2845)[ ](https://orcid.org/0000-0002-4503-2845)Muneaki Shimada  [https://orcid.org/0000-0003-1826-6723](https://orcid.org/0000-0003-1826-6723)[ ](https://orcid.org/0000-0003-1826-6723)Masato Tamate  [https://orcid.org/0000-0003-1447-9297](https://orcid.org/0000-0003-1447-9297)[ ](https://orcid.org/0000-0003-1447-9297)Hyun Woong Cho  [https://orcid.org/0000-0002-0724-9971](https://orcid.org/0000-0002-0724-9971)[ ](https://orcid.org/0000-0002-0724-9971)Jun Zhu  [https://orcid.org/0000-0003-1224-2771](https://orcid.org/0000-0003-1224-2771)[ ](https://orcid.org/0000-0003-1224-2771)[Hung-Hsueh Chou](Hung-Hsueh Chou)  [https://orcid.org/0000-0002-7049-3280](https://orcid.org/0000-0002-7049-3280)  \nCurrent treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT)  \nYusuke Kobayashi ,1 Muneaki Shimada ,2 Masato Tamate ,3  \nHyun Woong Cho ,4 Jun Zhu ,5 Hung-Hsueh Chou ,6,7 Hiroaki Kajiyama ,8 Aikou Okamoto ,9 Daisuke Aoki ,10 Sokbom Kang ,11 Jeong-Won Lee ,12 Jae-Weon Kim ,13 Jae-Hoon Kim ,14 Zhongqiu Lin ,15 Jihong Liu ,16  \nXiaohua Wu ,17 Hung-Cheng Lai ,18 Ting-Chang Chang ,6,19 Chyong-Huey Lai ,19 Yong Man Kim ,20 Takayuki Enomoto  21  \n1Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan 2Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Miyagi, Japan 3Department of Obstetrics and Gynecology, Sapporo Medical University, Hokkaido, Japan  \n4Department of Obstetrics and Gynecology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea  \n5Department of Gynecologic Oncology, Cancer Hospital of Fudan University, Shanghai, China  \n6Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan 7National Tsing Hua University, School of Medicine, Hsinchu, Taiwan  \n8Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan 9Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan 10International University of Health and Welfare Graduate School, Tokyo, Japan  \n11Center for Gynecologic Oncology, National Cancer Center, Goyang, Korea  \n12Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea  \n13Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea 14Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea  \n15Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China  \n16Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Ce","cbCaiukm2oYznKGC","https://ap.wps.com/l/cbCaiukm2oYznKGC","pdf",2837117,"English","# Overview of current treatment advances\n## Chemotherapy optimization and maintenance therapy\n## PARP inhibitors for biomarker-defined subgroups\n## Intraperitoneal chemotherapy strategy","[{\"question\":\"What recent advances are highlighted for ovarian cancer treatment?\",\"answer\":\"The document highlights improved chemotherapy protocols and the use of PARP inhibitors as maintenance therapy, contributing to better outcomes.\"},{\"question\":\"Which patient groups benefit most from PARP inhibitor maintenance?\",\"answer\":\"Patients with specific genetic or molecular profiles, including BRCA mutations and homologous recombination deficiency (HRD), are specifically noted.\"},{\"question\":\"What role does intraperitoneal chemotherapy play in the treatment strategies?\",\"answer\":\"The review addresses intraperitoneal chemotherapy administration as part of the current strategy set discussed for ovarian cancer.\"}]","Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT) | PDF",1790008418,48]